×
0 0.000896458987001325 -0.00313760645450472 -0.00380995069475575 -0.00313760645450472 -0.00739578664276121 0 0.00515463917525766
Stockreport

Insmed files U.S. marketing application for inhaled amikacin for type of lung disease; shares up 2% [Seeking Alpha]

INSMED (INSM)  More Company Research Source: Seeking Alpha
Last insmed earnings: 5/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.insmed.com
PDF Insmed files U.S. marketing application for inhaled amikacin for type of lung disease; shares up 2%Insmed (INSM+1.6%)submits a New Drug Application (NDA) to the FDA seeking approval for ALIS (amikacin liposome inhalation suspension) for the treatment of adult patients with nontuberculous mycobacterial lung disease caused byMycobacterium avium complex. There are currently no approved therapies in the U.S. for the condition.The company says it expects a six-month review period considering ALIS's Orphan Drug, Breakthrough Therapy and Qualified Infectious Disease Product (QIDP) status.Previously:Insmed's inhalable amikacin successful in late-stage study, shares up 77% premarket (Sept. 5, 2017)See all stocks on the move »Now read:The Time To Buy Things Is When They're On Sale! » [Read more]

IMPACT SNAPSHOT EVENT TIME: INSM
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS